Phase III trial for Romark's influenza drug underway

04/22/2013 | Pharmaceutical Business Review Online

Romark Laboratories has started patient enrollment for a late-stage study of its influenza drug NT-300, or nitazoxanide. The study will involve 1,400 patients with fever and other flu symptoms. The trial is expected to be finished during the 2013-2014 flu season.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA